What Is Hyperbaric Oxygen Therapy

Hyperbaric oxygen therapy (HBOT) is a medical treatment in which a person breathes 100% oxygen inside a chamber pressurized above normal atmospheric levels, typically between 1.3 and 3.0 atmospheres absolute (ATA). The increased pressure dissolves extra oxygen directly into blood plasma and body fluids, raising tissue oxygen concentrations well beyond what hemoglobin-bound oxygen can achieve. HBOT has both FDA-cleared medical applications and a growing set of investigational uses related to tissue repair, neurological recovery, and aging.

Oxygen is the final electron acceptor in mitochondrial energy production, and its supply constrains every repair and regeneration process in the body. Under normal conditions, nearly all oxygen travels bound to hemoglobin, and plasma carries only a small dissolved fraction. When tissue is damaged, inflamed, or poorly vascularized, local oxygen delivery often falls below the threshold needed for immune cell function, collagen synthesis, and stem cell mobilization. HBOT addresses this bottleneck directly by flooding tissues with dissolved oxygen independent of red blood cell delivery.

From a longevity perspective, HBOT has attracted interest because of its effects on several hallmarks of aging. Animal and preliminary human research has examined whether repeated HBOT sessions influence telomere length, senescent cell clearance, angiogenesis, and neuroplasticity. The therapy also modulates hypoxia-inducible factor (HIF) signaling in a paradoxical way: the return to normal pressure after a session creates a relative hypoxic signal that triggers adaptive gene expression. This intermittent hyperoxic-normoxic cycling may be more biologically relevant to longevity than the oxygen exposure alone.

Under normal sea-level conditions (1 ATA), arterial blood carries roughly 20 mL of oxygen per deciliter, almost entirely bound to hemoglobin. Plasma holds only about 0.3 mL/dL of dissolved oxygen. At 2.4 ATA breathing pure oxygen, dissolved plasma oxygen rises to approximately 5 to 6 mL/dL, a roughly 15 to 20 fold increase. This dissolved fraction can penetrate tissues that swollen or damaged capillaries cannot reach, because dissolved gas diffuses according to partial pressure gradients rather than requiring intact vasculature.

The elevated oxygen triggers several downstream cascades. Reactive oxygen species (ROS) at controlled levels activate nuclear factor erythroid 2-related factor 2 (Nrf2), upregulating the body's endogenous antioxidant defenses including superoxide dismutase, catalase, and glutathione peroxidase. Fibroblast proliferation accelerates, collagen deposition increases, and vascular endothelial growth factor (VEGF) expression rises, promoting angiogenesis in ischemic tissue. Simultaneously, high oxygen tension is directly bactericidal to many anaerobic pathogens, and it restores the oxidative burst capacity of neutrophils, which require oxygen to kill bacteria.

The intermittent nature of treatment sessions introduces a second layer of biology. When the patient exits the chamber and returns to normal atmospheric oxygen, the relative drop in oxygen tension activates HIF-1 alpha signaling, a pathway normally triggered by hypoxia. This repeated hyperoxic-normoxic cycling stimulates stem cell mobilization from bone marrow, enhances erythropoietin production, and may contribute to mitochondrial biogenesis. Some researchers hypothesize that this oscillating oxygen signal is what drives the reported effects on telomere elongation and senescent cell reduction observed in small human studies, though these findings require replication.

A first HBOT session begins with a screening intake where the clinician reviews medical history, current medications, and any conditions that might affect pressure tolerance. Patients change into cotton clothing (synthetic fabrics and personal electronics are not permitted in the oxygen-rich environment) and enter either a monoplace chamber, which holds one person lying down, or a multiplace chamber, which accommodates several people seated or reclined.

As the chamber pressurizes over 10 to 15 minutes, patients feel increasing pressure in their ears similar to descending in an airplane. Swallowing, yawning, or performing a Valsalva maneuver relieves this. Once at treatment depth, the sensation normalizes and patients can rest, sleep, or listen to audio. The treatment phase lasts 60 to 90 minutes at the prescribed pressure. Depressurization takes another 10 to 15 minutes. Afterward, most people feel mildly fatigued or relaxed; some report a sense of mental clarity. Initial sessions may cause temporary lightheadedness as the body adjusts to rapid oxygen fluctuations.

Standard medical protocols for wound healing and approved indications typically call for daily sessions (five days per week) over four to eight weeks, totaling 20 to 40 treatments. The pressure is usually set between 2.0 and 2.4 ATA, with each session lasting 90 to 120 minutes including pressurization and depressurization.

Investigational protocols for neurological conditions or longevity-oriented applications often extend to 40 to 60 sessions and may use slightly different pressure profiles. Some longevity clinics employ lower pressures (1.3 to 1.5 ATA) in mild or "soft" chambers for more frequent use, though the evidence for these lower-pressure protocols is less established. After completing a full course, some practitioners recommend periodic maintenance sessions (weekly or monthly), but no consensus guidelines exist for maintenance scheduling outside of approved medical indications.

Individual HBOT sessions at clinical facilities typically range from $150 to $450 per session, depending on the type of chamber (monoplace vs. multiplace), the treatment pressure, and geographic location. A full course of 40 sessions can therefore cost $6,000 to $18,000. Insurance coverage is generally available only for FDA-cleared indications with appropriate documentation; off-label and longevity-focused treatments are almost always out-of-pocket expenses.

Some patients purchase or rent personal mild hyperbaric chambers (typically limited to 1.3 ATA) for home use, with costs ranging from $5,000 to $25,000. These lower-pressure units do not replicate the protocols studied in clinical research at 2.0 ATA or higher, and their clinical equivalence has not been established. Clinics that offer package pricing for multi-session courses often provide per-session discounts of 10% to 30%.

HBOT has a strong evidence base for its FDA-cleared indications. Multiple randomized controlled trials support its use in diabetic foot ulcers, radiation-induced tissue injury, chronic refractory osteomyelitis, and decompression sickness. For these applications, the mechanisms are well understood and clinical outcomes are measurable. The Undersea and Hyperbaric Medical Society maintains a list of approved indications based on systematic evidence review.

The evidence for longevity and anti-aging applications is considerably thinner. A small prospective trial in healthy older adults reported increases in telomere length and decreases in senescent cell populations after 60 sessions at 2.0 ATA, but this study had no control group and a limited sample size. Research on traumatic brain injury and post-concussion syndrome includes several small randomized trials with mixed results; some show improvements in cognitive function and cerebral blood flow, while others fail to separate HBOT from sham pressurization effects. Animal studies consistently demonstrate neuroprotective and regenerative effects, but translating these to human protocols remains incomplete. The longevity field awaits larger, well-controlled trials to clarify whether the telomere and senescence findings are reproducible and clinically meaningful.

The most common side effects of HBOT are middle ear barotrauma (pain or pressure from inadequate equalization), sinus discomfort, and transient myopia caused by oxygen-induced lens changes that typically reverse within weeks of completing treatment. Oxygen toxicity seizures are rare at clinical pressures but represent the most serious acute risk; they occur more frequently at higher pressures and longer exposure times. Pulmonary oxygen toxicity can develop with extended protocols. Claustrophobia may be an issue in monoplace chambers. Fire risk exists because of the pure oxygen environment, requiring strict protocols around clothing and personal items. Individuals with a history of spontaneous pneumothorax, certain congenital spherocytosis variants, or concurrent use of specific chemotherapeutic agents should be evaluated carefully before treatment.